BR112021021875A2 - Composição farmacêutica e método de tratamento de hipertensão pulmonar - Google Patents

Composição farmacêutica e método de tratamento de hipertensão pulmonar

Info

Publication number
BR112021021875A2
BR112021021875A2 BR112021021875A BR112021021875A BR112021021875A2 BR 112021021875 A2 BR112021021875 A2 BR 112021021875A2 BR 112021021875 A BR112021021875 A BR 112021021875A BR 112021021875 A BR112021021875 A BR 112021021875A BR 112021021875 A2 BR112021021875 A2 BR 112021021875A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pulmonary hypertension
treating pulmonary
liposome
treating
Prior art date
Application number
BR112021021875A
Other languages
English (en)
Inventor
Chieh Chen Ko
Pei Kan
Fong Lin Yi
Original Assignee
Pharmosa Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmosa Biopharm Inc filed Critical Pharmosa Biopharm Inc
Publication of BR112021021875A2 publication Critical patent/BR112021021875A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica e método de tratamento de hipertensão pulmonar. a presente invenção se refere a uma composição farmacêutica que contém lipossomas, o referido lipossoma compreende uma bicamada lipídica externa; e um meio aquoso interno que inclui uma droga de ácido fraco com uma meia-vida de menos de 2 horas. também é fornecido o uso da composição farmacêutica divulgada neste documento para tratar hipertensão pulmonar com frequência de dosagem reduzida.
BR112021021875A 2019-05-14 2020-05-13 Composição farmacêutica e método de tratamento de hipertensão pulmonar BR112021021875A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847337P 2019-05-14 2019-05-14
PCT/US2020/032563 WO2020232046A1 (en) 2019-05-14 2020-05-13 Pharmaceutical composition of a weak acid drug and methods of administration

Publications (1)

Publication Number Publication Date
BR112021021875A2 true BR112021021875A2 (pt) 2021-12-28

Family

ID=73231174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021875A BR112021021875A2 (pt) 2019-05-14 2020-05-13 Composição farmacêutica e método de tratamento de hipertensão pulmonar

Country Status (13)

Country Link
US (1) US20200360320A1 (pt)
EP (1) EP3969002A4 (pt)
JP (1) JP7445315B2 (pt)
KR (1) KR20210149157A (pt)
CN (1) CN113811307A (pt)
AU (2) AU2020274094B2 (pt)
BR (1) BR112021021875A2 (pt)
CA (1) CA3139136A1 (pt)
IL (1) IL287912A (pt)
MX (1) MX2021013842A (pt)
SG (1) SG11202112530VA (pt)
TW (1) TWI757739B (pt)
WO (1) WO2020232046A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202415382A (zh) * 2022-09-30 2024-04-16 大陸商上海濟煜醫藥科技有限公司 脂質體藥物組合物及其製備方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
IL159334A0 (en) * 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US20100209538A1 (en) * 2009-02-18 2010-08-19 Cipolla David C Ph-modulated formulations for pulmonary delivery
WO2011092708A2 (en) * 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
ES2611187T3 (es) * 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
KR20150089087A (ko) * 2012-11-30 2015-08-04 인스메드 인코포레이티드 프로스타사이클린 조성물 및 이를 이용하기 위한 방법
EP2970369B1 (en) * 2013-03-14 2023-11-22 TheraSyn Sensors, Inc. Cholestosome vesicles for incorporation of molecules into chylomicrons
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
US20170246175A1 (en) * 2014-09-24 2017-08-31 Nanyang Technological University Sustained timolol maleate delivery from liposomes for glaucoma therapy and occular hypertension
TWI754659B (zh) * 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
CN106214641A (zh) * 2016-08-22 2016-12-14 沈阳鑫泰格尔医药科技开发有限公司 一种适用于水溶性药物的脂质体及其制备方法
BR112020001411A2 (pt) * 2017-07-24 2020-07-28 Pharmosa Biopharm Inc. composição farmacêutica e método para tratar uma doença respiratória
TWI696471B (zh) * 2018-05-07 2020-06-21 國邑藥品科技股份有限公司 用於控制曲前列環素的釋放之醫藥組成物

Also Published As

Publication number Publication date
CN113811307A (zh) 2021-12-17
EP3969002A1 (en) 2022-03-23
IL287912A (en) 2022-01-01
EP3969002A4 (en) 2023-01-11
WO2020232046A1 (en) 2020-11-19
TWI757739B (zh) 2022-03-11
CA3139136A1 (en) 2020-11-19
AU2020274094A1 (en) 2021-11-11
KR20210149157A (ko) 2021-12-08
JP7445315B2 (ja) 2024-03-07
US20200360320A1 (en) 2020-11-19
SG11202112530VA (en) 2021-12-30
TW202108145A (zh) 2021-03-01
JP2022532207A (ja) 2022-07-13
AU2023270346A1 (en) 2023-12-14
MX2021013842A (es) 2022-01-18
AU2020274094B2 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
NI202100009A (es) Métodos para reducir la necesidad de revascu
ECSP22018209A (es) Nanopart?culas lip?dicas mejoradas para el suministro de ?cidos nucleicos
Chen et al. Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
Wen et al. Ixora parviflora Protects against UVB‐Induced Photoaging by Inhibiting the Expression of MMPs, MAP Kinases, and COX‐2 and by Promoting Type I Procollagen Synthesis
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
BR112015025961A2 (pt) composto, composição cosmética ou farmacêutica, e, uso de um composto
DK1140139T3 (da) Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier
BRPI0510778B8 (pt) composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
AR105493A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112022005614A2 (pt) Composições de vesícula extracelular
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
BR112021021875A2 (pt) Composição farmacêutica e método de tratamento de hipertensão pulmonar
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
Jeong et al. Sphingosine kinase 1 activation enhances epidermal innate immunity through sphingosine-1-phosphate stimulation of cathelicidin production
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
BR112019005080A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para aumentar o tempo de estabilização de uma composição farmacêutica, para melhorar o desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
PH12020550513A1 (en) Composition of docetaxel liposomal injection with high drug loading
CL2019003562A1 (es) Derivados esteroideos con actividad terapéutica.
MX2021001820A (es) Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.